4NKS

Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3

Summary for 4NKS

• Entry DOI: 10.2210/pdb4nks/pdb
• Related: 4F63 4F64 4F65 4NK9 4NKA
• Descriptor: Fibroblast growth factor receptor 1, N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]-N~4~-[5-(2-phenylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine (3 entities in total)
• Functional Keywords: kinase, atp binding, phosphorylation, trans-membrane, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Homo sapiens (human)
• Cellular location: Cell membrane; Single-pass type I membrane protein: P11362
• Total number of polymer chains: 2
• Total formula weight: 71021.53

Authors

Norman, R.A.,Klein, T. (deposition date: 2013-11-13, release date: 2013-12-18, Last modification date: 2024-02-28)

Primary citation

Klein, T.,Tucker, J.,Holdgate, G.A.,Norman, R.A.,Breeze, A.L.
FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.
ACS Med Chem Lett, 5:166-171, 2014

PubMed Abstract: The binding of a ligand to its target protein is often accompanied by conformational changes of both the protein and the ligand. This is of particular interest, since structural rearrangements of the macromolecular target and the ligand influence the free energy change upon complex formation. In this study, we use X-ray crystallography, isothermal titration calorimetry, and surface-plasmon resonance biosensor analysis to investigate the binding of pyrazolylaminopyrimidine inhibitors to FGFR1 tyrosine kinase, an important anticancer target. Our results highlight that structurally close analogs of this inhibitor series interact with FGFR1 with different binding modes, which are a consequence of conformational changes in both the protein and the ligand as well as the bound water network. Together with the collected kinetic and thermodynamic data, we use the protein-ligand crystal structure information to rationalize the observed inhibitory potencies on a molecular level.

PubMed: 24900792
DOI: 10.1021/ml4004205

Experimental method

X-RAY DIFFRACTION (2.5 Å)